DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is unclear whether dipeptidylpeptidase-4 (DPP-4) inhibition can counteract the impairment of cognitive function and brain injury caused by transient cerebral ischemia in type 2 diabetes. The present study was undertaken to test our hypothesis that linagliptin, a DPP-4 inhibitor, administration following transient cerebral ischemia can ameliorate cognitive impairment and brain injury in diabetic mice. METHODS: db/db mice, a model of obese type 2 diabetes, were subjected to transient cerebral ischemia by 17 min of bilateral common carotid artery occlusion (BCCAO), and were administered (1) vehicle or (2) linagliptin for 8 weeks or 1 week. For the long-term experiment on 8 weeks of linagliptin treatment, cognitive function, and volume and neuronal cell number of hippocampus and cortex were estimated in each group of mice. For the short-term experiment on 1 week of linagliptin treatment, cerebral IgG extravasation, Iba-1 positive cell number (reactive microglia), oxidative stress, and claudin-5 and gp91phox protein levels were measured in each group of mice. RESULTS: Linagliptin administration almost completely suppressed the circulating DPP-4 activity in db/db mice, but did not significantly reduce blood glucose or ameliorate glucose intolerance in db/db mice. Linagliptin administration following transient cerebral ischemia significantly counteracted cognitive impairment in diabetic mice, as estimated by water maze test and passive avoidance test. Linagliptin administration ameliorated the decrease in cerebral volume and neuronal cell number in hippocampus and cortex of diabetic mice. Linagliptin administration significantly reduced the increase in cerebral IgG extravasation and the increase in reactive microglia caused by transient cerebral ischemia in diabetic mice. Furthermore, linagliptin significantly suppressed the increase in cerebral oxidative stress in transient cerebral ischemia-subjected diabetic mice. Furthermore, linagliptin significantly increased cerebral claudin-5 and significantly decreased gp91phox in diabetic mice subjected to transient cerebral ischemia. CONCLUSIONS: DPP-4 inhibition with linagliptin counteracted cognitive impairment and brain atrophy induced by transient cerebral ischemia in diabetic mice, independently of blood glucose lowering effect. This cerebroprotective effect of linagliptin was associated with the suppression of blood-brain barrier disruption and the attenuation of cerebral oxidative stress. Thus, our present work highlights DPP-4 inhibition as a promising therapeutic strategy for cognitive impairment and cerebral vascular complications in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125 · cited 1×
“Introduction Type 2 diabetes is one of the major risk factors contributing to stroke, ischemic heart disease, or heart failure [1, 2], and is known to be associated with the increased risk of cognitive decline such as Alzheimer’s disease and vascular dementia [3–5].”
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study
Fox, C. S., Coady, S., Sorlie, P. D., D’Agostino, R. B., Pencina, M. J., Vasan, R. S., Meigs, J. B., Levy, D., & Savage, P. J. (2007) · Circulation · doi:10.1161/circulationaha.106.658948 · Cited by 656 · cited 1×
“Introduction Type 2 diabetes is one of the major risk factors contributing to stroke, ischemic heart disease, or heart failure [1, 2], and is known to be associated with the increased risk of cognitive decline such as Alzheimer’s disease and vascular dementia [3–5].”
BackgroundIs Breakdown of the Blood-Brain Barrier Responsible for Lacunar Stroke, Leukoaraiosis, and Dementia?
Wardlaw, J. M., Sandercock, P. A. G., Dennis, M. S., & Starr, J. (2003) · Stroke · doi:10.1161/01.str.0000058480.77236.b3 · Cited by 628
Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama Study
Matsuzaki, T., Sasaki, K., Tanizaki, Y., Hata, J., Fujimi, K., Matsui, Y., Sekita, A., Suzuki, S. O., Kanba, S., Kiyohara, Y., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181eee25f · Cited by 432
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423 · cited 1×
“Oral glucose tolerance test (OGTT) The oral glucose tolerance test was performed as previously described [25].”
Self-citationInsulin metabolism and the risk of Alzheimer disease: The Rotterdam Study
Schrijvers, E. M. C., Witteman, J. C. M., Sijbrands, E. J. G., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4f6 · Cited by 328
Do in vivo Experimental Models Reflect Human Cerebral Small Vessel Disease? a Systematic Review
Hainsworth, A. H., & Markus, H. S. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.91 · Cited by 240 · cited 1×
“blood-brain barrier plays a key role in the pathophysiology of brain function, stroke, and dementia [32–35].”
BackgroundSystemic low‐molecular weight drug delivery to pre‐selected neuronal regions
Campbell, M., Humphries, M. M., Kiang, A., Nguyen, A. T. H., Gobbo, O. L., Tam, L. C. S., Suzuki, M., Hanrahan, F., Ozaki, E., Farrar, G. ‐., et al. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100126 · Cited by 42 · cited 1×
“To address the underlying molecular mechanism, we examined the effect of linagliptin on cerebral claudin-5 and gp91phox levels in cerebral ischemia-subjected diabetic mice, since claudin-5 [36, 37] is a main cerebral endothelial tight junction protein which plays a major role in blood-brain”
Background
Cited by
Tang, H., Shao, H., Shaaban, C. E., Yang, K., Brown, J., Anton, S., Wu, Y., Bress, A., Donahoo, W. T., DeKosky, S. T., et al. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18306 · Cited by 106
Olivares, M., Schüppel, V., Hassan, A. M., Beaumont, M., Neyrinck, A. M., Bindels, L. B., Benítez-Páez, A., Sanz, Y., Haller, D., Holzer, P., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01900 · Cited by 72
Marlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61
Metadata
- Authors
- Ma, M., Hasegawa, Y., Koibuchi, N., Toyama, K., Uekawa, K., Nakagawa, T., Lin, B., & Kim-Mitsuyama, S.
- Venue
- Cardiovascular Diabetology
- Published
- 2015-05-20
- Volume
- 14
- Issue
- 1
- Pages
- 54-54
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W2098047743
- Cited by
- 72
- References
- 9
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. https://app.cochat.ai/papers/10.1186/s12933-015-0218-z
- The paper
- Ma, M., Hasegawa, Y., Koibuchi, N., Toyama, K., Uekawa, K., Nakagawa, T., Lin, B., & Kim-Mitsuyama, S. (2015). DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-015-0218-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.